The quarterly earnings season has seen roughly 86% of firms reported results that have topped analysts’ estimates. S&P 500 earnings growth for the period is seen rising 9.3% versus a year ago, on ...

Today’s ACT Brief explores how eConsent is modernizing participant engagement, highlights new data on global representation in breast cancer trials, and examines Moderna’s decision to halt its Phase ...

A bipartisan group of senators is working to draft legislation to reform a fast-growing hospital drug discount program designed to help low-income patients.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

Founder of Peloza Spine joined national healthcare leaders to discuss physician-led innovation and operational excellence in ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.

Moderna's experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna’s highly touted cytomegalovirus vaccine — long billed as its next big win after its Covid-19 shot — failed a Phase 3 ...

US biotech Moderna (Nasdaq: MRNA) is discontinuing its once-promising vaccine for congenital cytomegalovirus (CMV) after the shot failed to prevent primary infection in healthy women during a Phase ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.